tiprankstipranks

Scholar Rock ‘easier to own’ after Biohaven data, says Jefferies

Jefferies analyst Michael Yee notes that Biohaven’s (BHVN) Phase 3 study of taldefgrobep alfa failed on the primary endpoint with no statistical separation versus placebo on the primary endpoint of MFM-32 at 48 weeks. Following the competitor data, Scholar Rock (SRRK) is now “a more derisked cleaner story and easier to own,” says the analyst, who reiterates a Buy rating and $50 price target on Scholar Rock shares ahead of obesity proof of concept data due in Q2 of 2025 and the SMA launch planned for Q4 of 2025.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue